Overview: ToRCH Panel IgG Extended
Introduction: The ToRCH Panel IgG Extended is a diagnostic tool designed for extended congenital infection screening using serum samples. In India, extended IgG testing (Toxoplasma, Rubella, CMV, HSV-1/HSV-2) assesses past exposure/immunity in pregnancy, crucial for risk stratification in high-prevalence settings. High morbidity from under-testing in rural/low-SES pregnant women, limited serology labs, delayed immunity confirmation leading to unnecessary anxiety or missed high-risk cases. Per obstetrics practices aligned with ICMR, FOGSI, and National Health Mission guidelines, the test employs immunoassay for Toxoplasma IgG, Rubella IgG, CMV IgG, HSV-1 IgG, and HSV-2 IgG over 1â€"2 days with high accuracy, valuable for baseline immunity profiling in early pregnancy. This diagnostic falls under infectious disease screening and targets pregnant women in first trimester or high-risk, addressing accurate detection to guide further IgM/avidity or reassurance. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling detailed ToRCH immunity assessment and reducing congenital infection burden. Its serum-based approach ensures reliable IgG detection.
Other Names: TORCH IgG Ext Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry/immunology/clinical pathology, compliant with 2025 standards.
Historical Milestone: Extended ToRCH IgG standard in antenatal care; in India, routine in high-risk pregnancies.
Purpose: The test assesses 5 parameters including Toxoplasma IgG to guide congenital infection screening, assess past exposure/immunity, inform further testing.
Test Parameters: 1. Toxoplasma IgG, 2. Rubella IgG, 3. CMV IgG, 4. HSV-1 IgG, 5. HSV-2 IgG.
Pretest Condition: No fasting required; patients should be pregnant.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve antibody integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on gestational age, prior infections.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of recent infection including fetal defects, benefits of extended screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive IgG indicates past exposure/immunity; HSV-2 positivity flags higher neonatal risk, necessitating specialist input.
Specialist Consultation: Obstetricians or infectious disease specialists should be consulted for management.
Additional Supporting Tests: IgM, avidity for recent infection confirmation.
Test Limitations: IgG only (no acute status); comprehensive approach required.
References: Indian Journal of Obstetrics and Gynaecology 2024, TORCH Studies India 2023.
